Sanofi (0A2V.L)
- GlobeNewswire
Press Release: Online availability of Sanofi’s half-year financial report for 2024
Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K. This document may be found on the company’s corporate website: www.sanofi.com and downloaded from the “Investors” page, under the
- GlobeNewswire
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded Paris, July 25, 2024 Q2 sales growth of 10.2% at CER and business EPS(1) of €1.73 Dupixent sales up 29.2% to €3,303 million; target of ~€13 billion in 2024 unchangedPharma launches up 80.4% to €689 million, led by ALTUVIIIO, Nexviazyme, Rezurock, and SarclisaVaccines sales -4.8% due to COVID-19 sales in 2023Opella (former Sanofi Consumer Healthcare) up 9.6%, driven by the Qunol acquisitionResearch and Development expense
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares – June 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,537,214,304 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
